Alastair Burt
Alastair Burt
Verified email at adelaide.edu.au
Title
Cited by
Cited by
Year
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD
P Angulo, JM Hui, G Marchesini, E Bugianesi, J George, GC Farrell, ...
Hepatology 45 (4), 846-854, 2007
21722007
Serum markers detect the presence of liver fibrosis: a cohort study
WMC Rosenberg, M Voelker, R Thiel, M Becka, A Burt, D Schuppan, ...
Gastroenterology 127 (6), 1704-1713, 2004
12022004
The natural history of nonalcoholic fatty liver: a follow‐up study
MR Teli, OFW James, AD Burt, MK Bennett, CP Day
Hepatology 22 (6), 1714-1719, 1995
11391995
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers
IN Guha, J Parkes, P Roderick, D Chattopadhyay, R Cross, S Harris, ...
Hepatology 47 (2), 455-460, 2008
7282008
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management
S McPherson, T Hardy, E Henderson, AD Burt, CP Day, QM Anstee
Journal of hepatology 62 (5), 1148-1155, 2015
6952015
Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
S McPherson, SF Stewart, E Henderson, AD Burt, CP Day
Gut 59 (9), 1265-1269, 2010
6182010
EASL clinical practical guidelines: management of alcoholic liver disease
European Association For The Study Of The Liver
Journal of hepatology 57 (2), 399-420, 2012
5582012
Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver
MR Teli, CP Day, OFW James, AD Burt, MK Bennett
The Lancet 346 (8981), 987-990, 1995
5281995
Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
NF Olivieri, GM Brittenham, CE McLaren, DM Templeton, RG Cameron, ...
New England Journal of Medicine 339 (7), 417-423, 1998
4631998
Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients
SU Nielsen, MF Bassendine, AD Burt, C Martin, W Pumeechockchai, ...
Journal of virology 80 (5), 2418-2428, 2006
4312006
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
YL Liu, HL Reeves, AD Burt, D Tiniakos, S McPherson, JBS Leathart, ...
Nature communications 5 (1), 1-6, 2014
4262014
Diagnosis and interpretation of steatosis and steatohepatitis.
AD Burt, A Mutton, CP Day
Seminars in diagnostic pathology 15 (4), 246-258, 1998
4121998
Liver fibrosis
K Wallace, AD Burt, MC Wright
Biochemical Journal 411 (1), 1-18, 2008
4052008
Nonalcoholic fatty liver disease
EM Brunt, VWS Wong, V Nobili, CP Day, S Sookoian, JJ Maher, ...
Nature reviews Disease primers 1 (1), 1-22, 2015
3752015
Elevated endotoxin levels in non-alcoholic fatty liver disease
AL Harte, NF da Silva, SJ Creely, KC McGee, T Billyard, ...
Journal of inflammation 7 (1), 1-10, 2010
3672010
Carriage of the PNPLA3 rs738409 C> G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma
YL Liu, GL Patman, JBS Leathart, AC Piguet, AD Burt, JF Dufour, CP Day, ...
Journal of hepatology 61 (1), 75-81, 2014
3242014
Cellular senescence drives age-dependent hepatic steatosis
M Ogrodnik, S Miwa, T Tchkonia, D Tiniakos, CL Wilson, A Lahat, CP Day, ...
Nature communications 8 (1), 1-12, 2017
3142017
Histologic spectrum of alcoholic liver disease
RNM MacSween, AD Burt
Seminars in liver disease 6 (03), 221-232, 1986
3051986
Pathology of the liver
RNM MacSween, AD Burt, BC Portmann, KG Ishak, PP Anthony, ...
Gulf Professional Publishing, 2002
2982002
Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease
J Parkes, P Roderick, S Harris, C Day, D Mutimer, J Collier, M Lombard, ...
Gut 59 (9), 1245-1251, 2010
2832010
The system can't perform the operation now. Try again later.
Articles 1–20